Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Cancer Res. 2012 Jun 27;72(16):4154–4164. doi: 10.1158/0008-5472.CAN-11-2848

FIGURE 3. Combined inhibition of EGFR and tankyrase permanently impairs clonogenic outgrowth of NSCLC cells.

FIGURE 3

A) H322C and HCC4006 cells were treated in triplicate with DMSO or gefitinib (500 nM for H322C; 20 nM for HCC4006) and/or the TNKS inhibitors XAV939 (5 µM) or endo-IWR1 (20 µM) for 4 days, and then replated without drugs for colony forming assays. B) H322C cells were treated as in Figure 2B for 72h and cell cycle profiles analyzed by saponin/PI staining. C) H322C cells were treated with DMSO or gefitinib (500 nM) and/or XAV939 (5 µM) for 5 days, and then stained for senescence-associated β-galactosidase (sa-β-gal) activity. For A and C, * indicates p<0.05, ** p<0.01, and *** p<0.001. D) HCC4006 cells were treated for 24 hours with DMSO or gefitinib (30 nM/GEFlo or 60 nM/GEFhi) and/or XAV939 (3 µM) (n=3/condition), and AXIN-2, BIRC5 and MYC mRNA levels determined by RT-PCR. Dotted line at y=1 represents levels in DMSO-treated samples.